[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626501":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":64,"collaborators":20,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":20,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Ankara University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"F-18-TFB PET\u002FCT arm","EXPERIMENTAL","DTC patients who underwent F-18-TFB PET\u002FCT",[13],"Diagnostic Test: F-18-Tetrafluoroborate PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","F-18-Tetrafluoroborate PET\u002FCT","F-18-Tetrafluoroborate whole body PET\u002FCT",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Mine Araz, Assoc.Prof.","Ankara University Medical School Nuclear Medicine Department","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Mine Araz, Assoc.Prof.Dr.","CONTACT","+905326667313","minesoylu@yahoo.com",[33,51],{"facility":24,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":20,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Ankara","06590","Turkey (Türkiye)",{"type":39,"coordinates":40},"Point",[41,42],32.85427,39.91987,{"lat":42,"lon":41},[45,46,49],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":47,"role":48,"phone":20,"phoneExt":20,"email":20},"Nuriye Ozlem Küçük, Prof.Dr.","SUB_INVESTIGATOR",{"name":50,"role":48,"phone":20,"phoneExt":20,"email":20},"Cigdem Soydal, Prof.Dr.",{"facility":52,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":20,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Hacettepe University Medical School Nuclear Medicine Department",{"type":39,"coordinates":54},[41,42],{"lat":42,"lon":41},[57,62],{"name":58,"role":29,"phone":59,"phoneExt":60,"email":61},"Murat Fani Bozkurt, Prof.Dr.","05326667313","+905324924890","fanibozkurt@gmail.com",{"name":63,"role":48,"phone":20,"phoneExt":20,"email":20},"Bilge Volkan Salancı, Prof.Dr.",{"type":25,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Mine Araz","Assoc.Prof.Dr. Mine Araz","100626501","f-18-tetrafluoroborate-petct-in-differentiated-thyroid-cancer-100626501",false,"NCT07436455","F-18 Tetrafluoroborate PET\u002FCT in Differentiated Thyroid Cancer","NISDETECT","Inclusion Criteria:\n\n* Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy\n* Being evaluated for lesion detection due to elevated serum Tg and\u002For ATg levels during post-treatment follow-up\n* Negative or equivocal I-131 whole-body scan findings\n* Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \\[ECOG\\]\u002FWorld Health Organization \\[WHO\\] performance status)\n* Giving written informed consent\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy or breastfeeding\n* Failure to provide written informed consent","ALL","18 Years",{"count":77,"type":78},50,"ESTIMATED","INTERVENTIONAL",[81],"NA","In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and\u002For ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET\u002FCT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity.\n\nF-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies.\n\nThe primary aim of this study is to comparatively evaluate the role of F-18 TFB PET\u002FCT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET\u002FCT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and\u002For ATg levels during follow-up after radioactive iodine therapy.\n\nThe secondary aims are to investigate the factors predicting F-18 TFB PET\u002FCT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET\u002FCT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.",[84,85],"Thyroid Cancer","Differentiated Thyroid Cancer",[87,88,89],"F-18-tetrafluoroborate","PET\u002FCT","NIS","2026-02-21",{"date":92,"type":93},"2026-02-27","ACTUAL",{"date":95,"type":93},"2025-11-01",{"date":97,"type":78},"2026-10-01",{"name":5,"class":6},2]